Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

The company continued to benefit from increasing sales of Keytruda. However, Merck’s outlook for 2025 fell short of expectations, weighing on its stock. As an aside, ready for a rebound?

TD Cowen has downgraded Merck (NYSE:MRK) to hold from buy, citing Keytruda's impending loss of market exclusivity, or LOE. The bank said it no longer sees "viable arguments" for outperformance in the ...

TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of exclusivity for ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

Anthony Tata’s nomination for a key Defense Department position also failed during Trump’s first term, and wouldn’t you know it, he’s also back. The New York Times reported: President ...

Israeli forces were withdrawing from a key corridor that bisects the Gaza Strip on Sunday as part of Israel’s commitments under a tenuous ceasefire deal with Hamas. “We are preparing to ...

Robert F. Kennedy Jr. faces a clear path forward to a full Senate confirmation thanks in large part to a key yes vote from a GOP physician-senator facing a 2026 primary challenge. During a ...

The pressure piece is key here, and the Eagles should have multiple avenues to beat Kansas City up front. The weak link on the offensive line is right tackle Jawaan Taylor, who is susceptible to ...